Skip to content

Compare

Semaglutide vs tirzepatide

What is the difference between semaglutide and tirzepatide?

In short

Semaglutide acts on one gut-hormone receptor (GLP-1); tirzepatide acts on two (GIP and GLP-1). Both are once-weekly injections, both are prescription medicines approved by the FDA under brand names for type 2 diabetes and for chronic weight management, and both need medical evaluation and monitoring. Which one, if either, fits a given person depends on history, labs, goals, tolerance and cost, and that decision is made by a licensed provider, not by a comparison table.

Semaglutide compared with Tirzepatide
SemaglutideTirzepatide
How it worksGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
FDA-approved brand productsOzempic and Rybelsus (type 2 diabetes), Wegovy (chronic weight management)Mounjaro (type 2 diabetes), Zepbound (chronic weight management; obstructive sleep apnea in obesity)
How it is takenOnce-weekly injection (Rybelsus is a daily tablet)Once-weekly injection
DoseStarted low and stepped up over weeks to a maintenance dose set by the prescriberStarted low and stepped up over weeks to a maintenance dose set by the prescriber
Common side effectsNausea, constipation, diarrhoea, reduced appetite, mostly during dose increasesNausea, constipation, diarrhoea, reduced appetite, mostly during dose increases
Compounded versionsNot FDA-approved products; availability depends on current FDA policy and pharmacy licensureNot FDA-approved products; availability depends on current FDA policy and pharmacy licensure
Who decidesA licensed provider after history and labsA licensed provider after history and labs

The one real mechanical difference

Both medicines imitate gut hormones that slow stomach emptying, lower appetite and improve blood-sugar control. Semaglutide works through the GLP-1 receptor alone. Tirzepatide adds a second target, GIP, which is why it is described as a dual agonist. In head-to-head and pooled studies tirzepatide has generally produced larger average weight loss, but averages are not individuals: tolerance, other conditions, cost and what a person has already tried all move the decision.

Brand products and what the FDA has approved

Semaglutide is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity. Those are the FDA-approved products. A compounded preparation of either molecule is not an FDA-approved product and is not a generic; the FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed.

What a provider looks at before choosing either

At Vivo the evaluation comes first: glucose and HbA1c, fasting insulin, a lipid panel, thyroid, sex hormones and liver and kidney markers, alongside history, medications and goals. Some people are not candidates for either medicine. Where one is appropriate, the provider sets the starting dose, the step-up schedule and the follow-up, and the plan protects muscle rather than chasing the scale.

Getting started at Vivo is a $200 onboarding and initial consultation, or the $500 at-home lab package that includes it.

Side effects and monitoring

The common side effects are the same family for both: nausea, constipation or diarrhoea and reduced appetite, most noticeable when the dose steps up. Less common but serious risks are listed in each product's prescribing information, which is why these are prescription medicines with follow-up, not a subscription. Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, or a history of pancreatitis, needs that discussed before anything is prescribed.

Sources

  1. FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss
  2. FDA: Human drug compounding
  3. DailyMed: prescribing information for Wegovy, Ozempic, Zepbound and Mounjaro

Medically reviewed by: Vivo Clinical Team · Licensed medical providers · Last reviewed November 2026 · Educational information, not medical advice. Compounded medications are not FDA-approved products.

Next step

The comparison that matters is the one with your labs in it.

A licensed provider decides what fits you after your history and results are reviewed together.

Questions

Questions people ask next.

What comes up after semaglutide vs tirzepatide.

  • It has produced larger average weight loss in studies, but the right medicine for a given person depends on their history, labs, tolerance, cost and goals. A licensed provider makes that call after an evaluation.

  • No. Ozempic and Wegovy are FDA-approved products. A compounded preparation is made by a licensed pharmacy for an individual prescription and is not an FDA-approved product. Whether compounding is available at a given time depends on current FDA policy and pharmacy licensure.

  • Vivo's medical weight loss program evaluates GLP-1 medication where appropriate after labs and history. Not everyone is a candidate. Where medication is part of the plan, a licensed provider prescribes it and a vetted U.S. pharmacy partner fills it.

  • Getting started at Vivo is a $200 onboarding and initial consultation, or the $500 at-home lab package that includes it. Treatment cost depends on the plan your provider recommends and is discussed directly with the team. Vivo does not bill insurance.